PharmaVentures, a premier transaction advisory firm; a company involved in partnering, pharma M&A deals and strategic alliances, has named Mark Andrews as its new managing director, it was reported yesterday.

Prior to joining PharmaVentures, Andrews was a core member of the Corporate Finance M&A Life Science sector team at BDO in London, where he worked with clients especially in the outsourced pharma services and medical devices sectors. Earlier he was at Inventages. Prior to that he was at DEWB Venture Capital in Jena, Germany. His experience spans across the investment cycle, from sourcing through investment negotiation to hands-on portfolio management, driving towards exit negotiation.

Fintan Walton, PhD, chief executive of PharmaVentures, said, 'We are delighted to welcome Mark to PharmaVentures. He has an impressive track record in life science investments and deal-making. His wealth of experience will add significant value to our clients in their M&A and fundraising activities.'